金融界2025年8月12日消息，工银前沿医疗股票C(010685) 最新净值3.2900元，下跌0.81%。该基金近1个 月收益率7.38%，同类排名279|656；近6个月收益率28.87%，同类排名62|637；今年来收益率28.12%， 同类排名105|635。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月3日至今,担任工银瑞 信前沿医疗股票型基金基金经理。2018年7月30日至2019年12月23日起担任工银瑞信医药健康行业股票 型证券投资基金基金经理。2020年05月20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合 型证券投资基金基金经理。2025年4月9日起担任工银瑞信新经济灵活配置混合型证券投资基金(QDII)基 金经理。 工银前沿医疗股票C股票持仓前十占比合计59.44%，分别为：恒瑞医药（9.51%）、科伦药业 （9.16%）、信立 ...

Group 1: Resumption of Trading - Jin Chengzi plans to acquire 55% stake in Samit and will resume trading tomorrow; Samit specializes in high-precision fast-reflecting mirror business [1] - Quzhou Development intends to purchase 95.4559% of Xian Dao Electronics and will resume trading tomorrow; Xian Dao focuses on the R&D of sputtering targets and evaporation materials for vacuum coating [1] Group 2: Mergers, Acquisitions, and Capital Increases - China Shipbuilding's dissenting shareholders' acquisition request price is set at 30.02 yuan per share [2] - Jiangsu Suopu plans to raise no more than 1.5 billion yuan through a private placement for the ethylene acetate and EVA integration project (Phase I) [3] - Guangli Microelectronics is acquiring 100% of LUCEDA NV to strategically position itself in silicon photonics technology [4] Group 3: Share Buybacks, Increases, and Equity Transfers - Zhenlei Technology has raised its share buyback price from 38.13 yuan per share to 74 yuan per share [5] - Fuanna has conducted its first buyback of 1 million shares [6] - Shaanxi Jinye plans to repurchase shares worth between 40 million and 70 million yuan, with loans not exceeding 63 million yuan [7] - Donghua Energy's controlling shareholder's concerted action party has received a commitment letter for a special loan to increase holdings, not exceeding 225 million yuan [8] - Taimusi's controlling shareholder intends to transfer 29.99% of the company's shares, with Guangzhou State-owned Assets Supervision and Administration Commission becoming the actual controller [9] Group 4: External Investments and Daily Operations - Haikang obtained the clinical trial approval notice for the innovative drug HSK47977 tablets [10] - Rundou Co., Ltd. received approval for the listing application of glucosamine sulfate sodium chloride compound as a chemical raw material drug [11] - Beilu Pharmaceutical's subsidiary Haichang Pharmaceutical's iodine mepivacaine chemical raw material drug has been approved for listing [12] - Baiyun Airport signed a cooperation contract with China Duty Free Group for the operation of the T3 terminal's outbound duty-free project [13] - Guoshield Quantum plans to sign a sales contract worth 76.5418 million yuan with China Telecom Quantum Group for the sale of quantum key distribution hardware and software [14] Group 5: Performance Changes - Zhenlei Technology's net profit for the first half of 2025 is 62.3197 million yuan, a year-on-year increase of 1006.99%; the company continues to strengthen its advantages in special fields such as data links, electronic countermeasures, wireless communication terminals, next-generation radios, and phased array communications, achieving significant growth in orders and projects [15] - Jingchen Co., Ltd. reported a net profit of 497 million yuan for the first half of the year, a year-on-year increase of 37.12% [16] - China Unicom's net profit for the first half of 2025 is 6.349 billion yuan, a year-on-year increase of 5.1% [17] - Shuanghui Development's net profit for the first half of the year is 2.323 billion yuan, a year-on-year increase of 1.17%; the company plans to distribute 6.5 yuan per 10 shares [18] - Jinlongyu's net profit for the first half of the year is 1.756 billion yuan, a year-on-year increase of 60.07% [19]

证券日报网讯 8月12日晚间，海思科发布公告称，公司于近日收到国家药品监督管理局下发的《药物临 床试验批准通知书》，药品名称：HSK47977。 （文章来源：证券日报） ...

Group 1 - Jishi Media (吉视传媒) clarifies that it does not engage in "State-owned Cloud" related businesses and does not invest in currently released films [1] - Haishi Pharmaceutical (海思科) received approval for clinical trials of its innovative drug HSK47977, a potential First-In-Class treatment for non-Hodgkin lymphoma [2] - Baiyun Airport (白云机场) signed a 10-year cooperation contract with China Duty Free Group for operating the T3 terminal's outbound duty-free project [3] Group 2 - ST Huamei (ST华微) announced that it failed to rectify fund occupation issues by the deadline, leading to a stock suspension starting August 13, 2025 [4] - Zhenlei Technology (臻镭科技) reported a 73.64% increase in revenue to 205 million yuan and a 1006.99% increase in net profit to approximately 62.32 million yuan for the first half of 2025 [5] - Jiangte Electric (江特电机) announced a change in actual controllers to Wang Xin and Zhu Jun following a share transfer [6] Group 3 - ST Shengtun (ST盛屯) will remove other risk warnings and change its stock name to "Shengtun Mining" effective August 14, 2025, with a trading limit increase from 5% to 10% [7] - Jin Chengzi (金橙子) plans to acquire 55% of Samit Optoelectronics through a share issuance and cash payment, with stock resuming trading on August 13 [8][9] - China Unicom (中国联通) proposed a cash dividend of 1.112 yuan per 10 shares, totaling approximately 3.477 billion yuan [10] Group 4 - China Shipbuilding (中国船舶) announced the buyout price for dissenting shareholders at 30.02 yuan per share, with a premium of 28.25% over the closing price [11] - Shuangyi Technology (双一科技) disclosed plans by its controlling shareholder to reduce holdings by up to 1.31 million shares, representing 0.7923% of total shares [12] - ST Xiachuang (ST峡创) will remove other risk warnings and change its stock name to "Haixia Innovation" effective August 14, 2025 [13] Group 5 - Yuhua Tian (玉禾田) stated that the small shareholding of Zhiyuan Innovation in its subsidiary does not significantly impact its operations [14] - Baichuan Co. (百川股份) announced that its chairman plans to reduce his stake by up to 3% due to personal financial needs [14]

证券代码：002653 证券简称：海思科 公告编号：2025-089 海思科医药集团股份有限公司 关于获得创新药 HSK47977 片 一、 研发项目简介 HSK47977是公司自主研发的一种口服BCL6（人B细胞淋巴瘤因子 瘤细胞的发生和发展，拟用于非霍奇金淋巴瘤的治疗。根据国家药品 监督管理局关于发布《化学药品注册分类及申报资料要求》的通告 （2020年第44号）中化学药品注册分类的规定，本品属于化学药品1 类。 本品国内尚无同靶点药物进入临床阶段，是潜在的First-In- Class产品。同时，本品已于2025年7月完成与FDA的Pre-IND沟通，并 于同月完成向FDA的IND申报递交，正在审评中，未来有望实现中美同 步开发。 在多项临床前研究中，HSK47977均展现出强效的抗肿瘤活性以及 较强的靶点选择性和理想的安全窗，并且与BCL2抑制剂联合使用时可 实现协同抗癌效果，是一款极具开发潜力的药物。 二、风险提示 创新药研发周期长、环节多、风险高，容易受到一些不确定性因 素的影响，敬请广大投资者谨慎决策，注意防范投资风险。公司将根 据该项目的后续进展及时履行信息披露义务。 《药物临床试验批准通知书 ...

2024年1至12月份，海思科的营业收入构成为：医药行业占比99.23%，其他业务占比0.77%。 （文章来源：每日经济新闻） 海思科（SZ 002653，收盘价：56.95元）8月12日晚间发布公告称，海思科医药集团股份有限公司关于 获得创新药HSK47977片《药物临床试验批准通知书》的公告。 ...

海思科8月12日公告，近日收到国家药品监督管理局下发的《药物临床试验批准通知书》。HSK47977片 用于非霍奇金淋巴瘤的治疗，公司于2025年6月提交的临床试验申请符合药品注册要求，获得临床试验 批准。HSK47977是公司自主研发的口服BCL6PROTA C小分子制剂，能够靶向结合和降解BCL6蛋白， 抑制肿瘤细胞的发生和发展。该药品是国内首款进入临床阶段的同靶点药物，有望实现中美同步开发。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its self-developed oral BCL6 PROTAC small molecule drug, HSK47977, aimed at treating non-Hodgkin lymphoma [1] Group 1: Drug Development - HSK47977 targets and degrades the BCL6 protein, inhibiting the occurrence and development of tumor cells [1] - The drug is classified as a Class 1 chemical drug according to the regulations set forth in the announcement on chemical drug registration classification [1] - Preclinical studies have shown that HSK47977 exhibits strong anti-tumor activity, high target selectivity, and an ideal safety window [1] Group 2: Combination Therapy - HSK47977 can achieve a synergistic anti-cancer effect when used in combination with BCL2 inhibitors, indicating its significant development potential [1]

Core Viewpoint - The company received approval from the National Medical Products Administration for its drug "HSK47977," which is a novel oral BCL6 PROTAC small molecule formulation aimed at treating non-Hodgkin lymphoma [1] Group 1 - The drug HSK47977 is developed in-house by the company and targets the degradation of the BCL6 protein, which is crucial in the development and progression of tumor cells [1] - The approval signifies a significant step forward in the company's oncology pipeline, potentially enhancing its market position in cancer treatment [1]

HSK47977是公司自主研发的一种口服BCL6(人B细胞淋巴瘤因子6)PROTAC小分子制剂，可以靶向结合 和降解BCL6蛋白，进而抑制肿瘤细胞的发生和发展，拟用于非霍奇金淋巴瘤的治疗。 海思科（002653）(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的《药物临床试验 批准通知书》，涉及药品："HSK47977"。 ...